KYORIN Pharmaceutical Co., Ltd. (TYO:4569)
1,530.00
+7.00 (0.46%)
Jul 31, 2025, 12:44 PM JST
KYORIN Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 15,021 | 13,886 | 19,394 | 26,994 | 27,445 | Upgrade |
Short-Term Investments | 1,493 | 99 | - | 500 | 3,399 | Upgrade |
Cash & Short-Term Investments | 16,514 | 13,985 | 19,394 | 27,494 | 30,844 | Upgrade |
Cash Growth | 18.08% | -27.89% | -29.46% | -10.86% | -6.30% | Upgrade |
Receivables | 47,541 | 47,672 | 47,250 | 41,636 | 40,409 | Upgrade |
Inventory | 65,730 | 53,470 | 48,025 | 42,217 | 38,568 | Upgrade |
Other Current Assets | 6,349 | 4,183 | 4,361 | 5,029 | 4,206 | Upgrade |
Total Current Assets | 136,134 | 119,310 | 119,030 | 116,376 | 114,027 | Upgrade |
Property, Plant & Equipment | 30,303 | 28,950 | 25,834 | 24,334 | 23,896 | Upgrade |
Long-Term Investments | 21,831 | 23,882 | 24,469 | 27,140 | 25,074 | Upgrade |
Other Intangible Assets | 4,757 | 5,088 | 5,393 | 3,289 | 3,785 | Upgrade |
Long-Term Deferred Tax Assets | 591 | 448 | 1,316 | 783 | 343 | Upgrade |
Other Long-Term Assets | 2 | 1 | 3 | 2 | 1 | Upgrade |
Total Assets | 193,618 | 177,679 | 176,045 | 171,924 | 167,126 | Upgrade |
Accounts Payable | 15,517 | 14,265 | 13,762 | 10,896 | 6,985 | Upgrade |
Accrued Expenses | 2,226 | 2,198 | 2,182 | 2,295 | 2,206 | Upgrade |
Short-Term Debt | 7,400 | 10,100 | 10,300 | 10,300 | 10,300 | Upgrade |
Current Portion of Long-Term Debt | 200 | 10,200 | - | - | - | Upgrade |
Current Portion of Leases | 135 | 87 | 134 | 147 | 137 | Upgrade |
Current Income Taxes Payable | 3,176 | 923 | 2,027 | 530 | 476 | Upgrade |
Other Current Liabilities | 6,457 | 7,718 | 6,578 | 8,014 | 7,303 | Upgrade |
Total Current Liabilities | 35,111 | 45,491 | 34,983 | 32,182 | 27,407 | Upgrade |
Long-Term Debt | 20,235 | 435 | 10,636 | 10,836 | 11,036 | Upgrade |
Long-Term Leases | 469 | 124 | 207 | 341 | 409 | Upgrade |
Long-Term Deferred Tax Liabilities | 59 | 185 | - | 175 | 293 | Upgrade |
Other Long-Term Liabilities | 885 | 545 | 1,038 | 998 | 736 | Upgrade |
Total Liabilities | 57,334 | 46,897 | 50,585 | 47,417 | 42,465 | Upgrade |
Common Stock | 700 | 700 | 700 | 700 | 700 | Upgrade |
Additional Paid-In Capital | 4,752 | 4,752 | 4,752 | 4,752 | 4,752 | Upgrade |
Retained Earnings | 142,789 | 136,774 | 134,396 | 132,710 | 132,557 | Upgrade |
Treasury Stock | -17,349 | -17,350 | -17,666 | -17,671 | -17,671 | Upgrade |
Comprehensive Income & Other | 5,392 | 5,906 | 3,278 | 4,016 | 4,323 | Upgrade |
Shareholders' Equity | 136,284 | 130,782 | 125,460 | 124,507 | 124,661 | Upgrade |
Total Liabilities & Equity | 193,618 | 177,679 | 176,045 | 171,924 | 167,126 | Upgrade |
Total Debt | 28,439 | 20,946 | 21,277 | 21,624 | 21,882 | Upgrade |
Net Cash (Debt) | -11,925 | -6,961 | -1,883 | 5,870 | 8,962 | Upgrade |
Net Cash Growth | - | - | - | -34.50% | -3.89% | Upgrade |
Net Cash Per Share | -207.58 | -121.29 | -32.86 | 102.44 | 156.42 | Upgrade |
Filing Date Shares Outstanding | 57.46 | 57.45 | 57.3 | 57.3 | 57.3 | Upgrade |
Total Common Shares Outstanding | 57.46 | 57.45 | 57.3 | 57.3 | 57.3 | Upgrade |
Working Capital | 101,023 | 73,819 | 84,047 | 84,194 | 86,620 | Upgrade |
Book Value Per Share | 2371.97 | 2276.50 | 2189.38 | 2172.82 | 2175.51 | Upgrade |
Tangible Book Value | 131,527 | 125,694 | 120,067 | 121,218 | 120,876 | Upgrade |
Tangible Book Value Per Share | 2289.18 | 2187.93 | 2095.27 | 2115.43 | 2109.45 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.